Results 11 to 20 of about 113,281 (294)

The effects of DPP-4 inhibitor on hypoxia-induced apoptosis in human umbilical vein endothelial cells

Journal of Pharmacological Sciences, 2017
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral hypoglycemic agents for patients with type 2 diabetes mellitus and have potential antiatherosclerotic properties.
Akari Nagamine, Hiroshi Hasegawa, Naoko Hashimoto, Tomoko Yamada-Inagawa, Masanori Hirose, Yuka Kobara, Hiroyuki Tadokoro, Yoshio Kobayashi, Hiroyuki Takano   +8 more
doaj   +2 more sources

DPP-4 inhibitor attenuates toxic effects of indoxyl sulfate on kidney tubular cells. [PDF]

PLoS ONE, 2014
Diabetic nephropathy is a common causative factor of chronic kidney disease (CKD). DPP-4 inhibitor has the ability to improve kidney function and renal microvasculature.
Wei-Jie Wang, Chen-Hung Chang, Mao-Feng Sun, Sheng-Feng Hsu, Ching-Sung Weng   +4 more
doaj   +2 more sources

A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes

Lipids in Health and Disease, 2017
Background Previous studies suggest that dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium glucose cotransporter 2 (SGLT2) inhibitors have different effects on the lipid profile in patients with type 2 diabetes.
Seon-Ah Cha, Yong-Moon Park, Jae-Seung Yun, Tae-Seok Lim, Ki-Ho Song, Ki-Dong Yoo, Yu-Bae Ahn, Seung-Hyun Ko   +7 more
doaj   +2 more sources

A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4

Journal of Pharmacological Sciences, 2019
Dipeptidyl peptidase-4 (DPP-4) inhibitors not only improve impaired glucose tolerance in diabetes, but also have pleiotropic extra-pancreatic effects such as preconditioning effect for myocardial ischemia-reperfusion injury.
Takehiro Yamaguchi, Ayano Watanabe, Masako Tanaka, Masayuki Shiota, Mayuko Osada-Oka, Soichi Sano, Minoru Yoshiyama, Katsuyuki Miura, Shojiro Kitajima, Shinji Matsunaga, Shuhei Tomita, Hiroshi Iwao, Yasukatsu Izumi   +12 more
doaj   +2 more sources

Target trial emulation of DPP-4 Inhibitors in patients with T2DM for pulmonary tuberculosis: a nationwide observational data

BMC Medicine
Background Diabetes mellitus increases the risk of developing tuberculosis (TB) and negatively affects TB treatment outcomes. Dipeptidyl peptidase-4 (DPP-4) inhibitors are used in glycemic control but can also modulate immune pathways involved in immune ...
Yi-Geng Chen, James Cheng-Chung Wei, Fu-Shun Yen, Chen-Yu Sung, Yu-Han Huang, Teng-Shun Yu, Fuu-Jen Tsai, Chii-Min Hwu, Chih-Cheng Hsu   +8 more
doaj   +2 more sources

DPP-4 inhibitor anagliptin protects against hypoxia-induced cytotoxicity in cardiac H9C2 cells

Artificial Cells, Nanomedicine, and Biotechnology, 2019
Cardiovascular complications are the leading cause of mortality and morbidity in type 2 diabetes patients. Diabetes greatly increases the risk of heart disease; therefore, the management of diabetes often involves the prevention of heart disease.
Yunxiang Ma, Junkai Wang, Changhua Wang, Qiong Zhang, Yannan Xu, Huajin Liu, Xia Xiang, Jiangwei Ma   +7 more
doaj   +2 more sources

4-Hydroxyisoleucine as a Natural DPP-4 Inhibitor for Diabetes

Biology, Medicine & Natural Product Chemistry
Research on 4-hydroxyisoleucine, a natural compound found in several plant sources, shows potential as an antidiabetic agent through inhibiting the DPP-4 (dipeptidyl peptidase-4) enzyme.
Amir Thalib, Irma Putri Damayanti
doaj   +3 more sources

Teneligliptin, a DPP-4 Inhibitor, Improves Vascular Endothelial Function via Divergent Actions Including Changes in Circulating Endothelial Progenitor Cells. [PDF]

Diabetes Metab Syndr Obes, 2023
Naoyuki Akashi,1 Tomio Umemoto,1 Hodaka Yamada,2 Takayuki Fujiwara,3 Kei Yamamoto,1 Yousuke Taniguchi,1 Kenichi Sakakura,1 Hiroshi Wada,1 Shin-ichi Momomura,1 Hideo Fujita1 1Division of Cardiovascular Medicine, Jichi Medical University Saitama Medical ...
Akashi N, Umemoto T, Yamada H, Fujiwara T, Yamamoto K, Taniguchi Y, Sakakura K, Wada H, Momomura SI, Fujita H.   +9 more
europepmc   +2 more sources

Treatment progression in sulfonylurea and dipeptidyl peptidase-4-inhibitor cohorts of type 2 diabetes patients on metformin

Patient Preference and Adherence, 2016
Xiaomei Peng, Dingfeng Jiang, Dongju Liu, Oralee J Varnado, Jay P Bae Eli Lilly and Company, Global Patient Outcomes and Real World Evidence, Indianapolis, IN, USA Background: Metformin is an oral antidiabetic drug (OAD) widely used as first-line ...
Peng X, Jiang D, Liu D, Varnado OJ, Bae JP   +4 more
doaj   +1 more source

DPP-4 Inhibitor and Sulfonylurea Differentially Reverse Type 2 Diabetes-Induced Blood-Brain Barrier Leakage and Normalize Capillary Pericyte Coverage. [PDF]

Diabetes, 2023
Microvascular pathology in the brain is one of the suggested mechanisms underlying the increased incidence and progression of neurodegenerative diseases in people with type 2 diabetes (T2D).
Elabi OF, Karampatsi D, Vercalsteren E, Lietzau G, Nyström T, Klein T, Darsalia V, Patrone C, Paul G.   +8 more
europepmc   +2 more sources